Company / Cash & Equivalents
Opus Genetics, Inc. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.1M
FY2025
5-year range
$30.3M / $50.5M
FY2021-FY2025
Trend
+48.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $51M to $45M over the past 2 years.
Based on SEC 10-K filings.
$45M in FY2025 with a 3-year CAGR of +1.9%.
Declined from $51M to $45M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +1.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +1.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 48.7% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.1M | +48.7% |
| FY2024 | $30.3M | -40.0% |
| FY2023 | $50.5M | +18.5% |
| FY2022 | $42.6M | - |
| FY2021 | - | - |
| FY2013 | $13.5M | +9.3% |
| FY2011 | $12.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026